TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Positive topline results from a planned interim analysis of the DESTINY-Breast09 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) in combination ...
The MarketWatch News Department was not involved in the creation of this content. -- Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback